Suven Pharmaceuticals Ltd (SUVENPHAR) fair value: what the stock is really worth
As of Nov 11, 2026: fair value (intrinsic value) of Suven Pharmaceuticals Ltd stock ₹83.98, price ₹465, that is 81.9% below the price, quality 61 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.
How to read this chart
60‑month range ₹279.75 – ₹1,333 · fair‑value band ₹50.52 – ₹130.33 · the ₹464.55 price screens above the ₹83.98 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 12, 2026.
Follow Suven Pharmaceuticals in your weekly email
Every Wednesday you see whether Suven Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally.
Show moreShow less
It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies.
The company was founded in 1989 and is based in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Berhyanda Limited.
Stock analysis
Suven Pharmaceuticals Ltd (SUVENPHAR) currently trades at ₹464.55, while our model-based Fair Value estimate is ₹83.98, 82% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹138.69 per share, and 0 of the 24 models we run sit above the ₹464.55 price.
Bear case: the Asset-Based group reads lowest at ₹17.12, and 24 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: ₹50.52 (bear) to ₹130.33 (bull), the price of ₹464.55 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Suven Pharmaceuticals Ltd reported revenue of ₹12.0B in FY2025 versus ₹9.8B in FY2021, a compound +5.1%/yr. Reported net income was ₹2.6B in FY2025, compounding −7.5%/yr from FY2021.
Key figures
Market cap ₹411B (≈ $4.4B) Mid · P/E ratio 98.3 · P/S ratio 26.1 · EPS (TTM) ₹10.94 · Net margin 26.6% · Return on equity 15.9% · Return on assets (EBIT) 21.9% (5-year average) · Operating margin 31.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 78 out of 100 (low confidence).
What moves the price
The share trades about 33% below its 52-week high and 66% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −28% fair-value upside, at −82%, SUVENPHAR screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (₹17.12 to ₹160.79). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear₹50.52Fair Value ₹83.98Bull₹130.33
Price ₹464.55 · Downside -81.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (₹10.94 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+13.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.2%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−4.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−4.9%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.45% → 25%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+48.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +42.1% a year for the price.
Compare Suven Pharmaceuticals Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 607 stocks
Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score61 · Above median
Fair Value upside−81.9% · Bottom 25%
Profitability
Return on equity (12 months)15.9% · Top 25%
Return on assets8.7% · Top 25%
Net margin (12 months)26.6% · Top 25%
Operating margin (12 months)31.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)39.7% · Top 25%
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Suven Pharmaceuticals Ltd (SUVENPHAR) overvalued or undervalued?
As of Nov 12, 2026, our model estimates a fair value of ₹83.98 versus a price of ₹464.55, about 82% lower (overvalued).
What is the fair value of SUVENPHAR?
Our model-based fair value for Suven Pharmaceuticals Ltd is ₹83.98 (as of Nov 12, 2026), built from audited fundamentals. The current price: ₹464.55.
What is the quality score of SUVENPHAR?
Suven Pharmaceuticals Ltd has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Suven Pharmaceuticals Ltd (SUVENPHAR)?
Our model-based price target is the fair value of ₹83.98 (as of Nov 12, 2026) from 24 valuation models. Cautious scenario ₹50.52, optimistic scenario ₹130.33. It is a calculation from audited fundamentals, not an analyst target.
What is the Suven Pharmaceuticals Ltd stock forecast for 2026?
Our models put fair value at ₹83.98, about 82% lower versus a price of ₹464.55 (overvalued). Cautious scenario ₹50.52, optimistic scenario ₹130.33. The calculation is refreshed regularly with new filings.
What is the revenue of Suven Pharmaceuticals Ltd (SUVENPHAR)?
Suven Pharmaceuticals Ltd reported trailing-twelve-month revenue of about ₹10.5B (latest available figure, as of Nov 12, 2026).
What growth is priced into Suven Pharmaceuticals Ltd (SUVENPHAR)?
For today's price to be fair in a discounted-cash-flow model, Suven Pharmaceuticals Ltd would have to grow free cash flow by +48.0 % per year for five years (discount rate 12.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.2 % per year. As of Nov 12, 2026.
What discount rate (WACC) does the fair value of SUVENPHAR use?
Our models discount Suven Pharmaceuticals Ltd at 12.7 %: a base by market capitalisation (mid), damped by beta 1.13, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Suven Pharmaceuticals Ltd that is +48.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.7 %) and the same formula as our fair value.
How much growth has Suven Pharmaceuticals Ltd (SUVENPHAR) delivered so far?
Over the past 5 years revenue at Suven Pharmaceuticals Ltd grew +8.2 % a year. The price currently implies free-cash-flow growth of +48.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Suven Pharmaceuticals Ltd (SUVENPHAR) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Suven Pharmaceuticals Ltd (+48.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Suven Pharmaceuticals Ltd (SUVENPHAR)?
The free-cash-flow yield on the price is 1.12 %: that much free cash flow Suven Pharmaceuticals Ltd produces per unit of market value. When it exceeds the discount rate of our models (12.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Suven Pharmaceuticals Ltd (SUVENPHAR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Suven Pharmaceuticals Ltd it is ₹83.98 per share (as of Nov 12, 2026), against a price of ₹464.55. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Suven Pharmaceuticals Ltd stock overvalued or undervalued in 2026?
As of Nov 12, 2026, SUVENPHAR trades above its calculated fair value: price ₹464.55, fair value ₹83.98, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SUVENPHAR?
No. The price is what the market pays today (₹464.55); the fair value is what the company's own numbers justify (₹83.98). For Suven Pharmaceuticals Ltd the two are ₹380.57 per share apart. That gap is exactly why we show both numbers side by side.
How much is Suven Pharmaceuticals Ltd worth?
The market values Suven Pharmaceuticals Ltd at about ₹411B (market capitalisation, as of Nov 12, 2026). Per share that is ₹464.55; our models calculate a fair value of ₹83.98 per share.
What do the bullish and bearish scenarios say about SUVENPHAR?
Our models span a range for Suven Pharmaceuticals Ltd: cautious scenario ₹50.52, base ₹83.98, optimistic ₹130.33 per share (as of Nov 12, 2026, price ₹464.55). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SUVENPHAR?
Suven Pharmaceuticals Ltd trades at a price-to-earnings ratio of 98.3 (as of Nov 12, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹83.98 is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2021 to 2025), reported earnings: 34.8. Other multiples: P/B 24.3, P/S 39.2.
How solid is the balance sheet of Suven Pharmaceuticals Ltd (SUVENPHAR)?
Balance-sheet figures for Suven Pharmaceuticals Ltd (as of Nov 12, 2026): return on equity 15.9%, debt of 0.00 per unit of equity. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is SUVENPHAR from its 52-week high?
Suven Pharmaceuticals Ltd trades at ₹464.55, about 33% below its 52-week high of ₹691.30 and 66% above the low of ₹279.75 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of ₹83.98 is for.
Which stocks are comparable to Suven Pharmaceuticals Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Suven Pharmaceuticals Ltd stock attractive at the current price?
The data as of Nov 12, 2026: price ₹464.55, calculated fair value ₹83.98 (−82%), Quality Score 61/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SUVENPHAR calculated?
We run Suven Pharmaceuticals Ltd through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹83.98 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. Suven Pharmaceuticals Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Suven Pharmaceuticals Ltd (SUVENPHAR)?
The closing price on Nov 11, 2026 was ₹464.55. Our model-based fair value is ₹83.98, about 82% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Suven Pharmaceuticals Ltd right now?
The price sits above even our optimistic bull case (₹130.33). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹50.52 to ₹130.33) leaves room in how you read the outcome.
Key figures of Suven Pharmaceuticals Ltd
How large is the market capitalisation of Suven Pharmaceuticals Ltd (SUVENPHAR)?
The market capitalisation of Suven Pharmaceuticals Ltd is ₹411B (≈ $4.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Suven Pharmaceuticals Ltd (SUVENPHAR)?
The price-to-sales ratio of Suven Pharmaceuticals Ltd is 26.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Suven Pharmaceuticals Ltd (SUVENPHAR)?
Earnings per share at Suven Pharmaceuticals Ltd are ₹10.94 (price ÷ EPS = P/E 98.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Suven Pharmaceuticals Ltd (SUVENPHAR)?
The net margin of Suven Pharmaceuticals Ltd is 26.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Suven Pharmaceuticals Ltd (SUVENPHAR)?
The return on equity (ROE) of Suven Pharmaceuticals Ltd is 15.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Suven Pharmaceuticals Ltd (SUVENPHAR)?
On an EBIT basis the return on assets of Suven Pharmaceuticals Ltd is 21.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Suven Pharmaceuticals Ltd (SUVENPHAR)?
The operating margin of Suven Pharmaceuticals Ltd is 31.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Suven Pharmaceuticals Ltd (SUVENPHAR)?
Revenue at Suven Pharmaceuticals Ltd is growing +39.7% versus a year earlier (3y avg −2.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Suven Pharmaceuticals Ltd (SUVENPHAR)?
Earnings per share at Suven Pharmaceuticals Ltd are growing +75.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Suven Pharmaceuticals Ltd (SUVENPHAR) carry?
The net debt of Suven Pharmaceuticals Ltd is ₹43.6M (fiscal year 2023, ≈ 0.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Suven Pharmaceuticals Ltd in the live analysis
One click puts Suven Pharmaceuticals Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 12, 2026